Insider trade

CEO purchased ~$9M of BSX shares in the open market

Traded Aug 3, 2026 · Filed Aug 5, 2026

~$9M
Reported value · 186K sh @ $48.3323: 1.59M
Holds after · shares reported: -10.7%
stock since the trade · S&P 500 +0.8%, $48.43 → $43.23 on Oct 1

Why it stands out

The boss of Boston Scientific spent $9M of their very own money to buy Boston Scientific shares. 3 other people at Boston Scientific bought some too, in the same month. Their pile of Boston Scientific shares grew by 13%.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 3, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 5, 2026

CEO$1M+Holdings +13%4 insiders bought in 30d

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$9,001,408

Shares × reported transaction price

Size band

$1M+

Ownership change

+13.3%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

4 distinct insiders in 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs CEO pay

This purchase equals about 38% of the CEO's reported total pay for fiscal 2025 ($23.5M)

Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-18. The proxy names Michael F. Mahoney as CEO for that year. A size comparison, not a judgement

Timing vs results

5 days after results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $48.43 on Aug 3, 2026, 14% above its 52-week low and 55% below its high, after a 7% rise over the previous 30 trading days

52-week range $42.63 (Jul 14, 2026) to $108.14 (Sep 8, 2025), 9% of the way up, from 251 adjusted closes. 30 trading days earlier: $45.29 on Jun 18, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Mar 5, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

2 such cases were open. In re: Boston Scientific Corporation Securities Litigation, docket 1:26-cv-40075, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+4.8%	+1.2%	+3.6%
30 days	-8.8%	-0.3%	-8.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-006950
Filed / recorded: Aug 5, 2026, 8:15 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: BOSTON SCIENTIFIC CORP
Issuer CIK: 885725
Ticker: BSX
Reporting person: Michael F Mahoney
Relationship: Director, Officer
Officer title: Chairman, President & CEO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 3, 2026
Transaction code: P
Shares / units: 186,240
Price per share: $48.3323
Acquired / disposed: Acquired (A)
Shares owned after: 1,590,024
Ownership form: Direct
Amendment: No

Footnotes from the filing

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.